Browse by Poster Author

Skip to main content

iwCLL 2025 Main banner

iwCLL X / Twitter

Browse by Poster Author

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

U
Ujjani, Chaitra

Fred Hutchinson Cancer Center / University of Washington School of Medicine
1803 - Real-world Treatment Outcomes among Patients with High-Risk CLL/SLL Receiving Venetoclax-Based Therapy in 1L or 2L: An Updated International Study
Chaitra Ujjani
Favorite
Umutbayeva, Ayazhan

Dana-Farber Cancer Institute
1001 - IgM Monoclonal Gammopathy Arises Directly from MBL/CLL Cells: Evidence from Proteomic Analyses
Ayazhan Umutbayeva
Favorite
Uría, Rita

Research Laboratory on Chronic Lymphocytic Leukemia, Institut Pasteur, Uruguay
1013 - The S100A9/EMMPRIN axis is involved in chronic lymphocytic leukemia progression and offers novel therapeutic opportunities
Rita Uría
Favorite
1018 - Unraveling the NOTCH1/MSI2/c-MYC Signaling Pathway Reveals a Novel Vulnerability in Chronic Lymphocytic Leukemia Progression
Rita Uría
Favorite
1211 - Unraveling a poor-prognosis CLL subgroup: from IGHV bias and AID activation to altered T-cell profiles
Rita Uría
Favorite
Urban, Aleksandra

Oslo University Hospital
1441 - A functional prognostic model predicts progression free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax
Aleksandra Urban
Favorite
Urbanová, Renata

Department of Hemato-Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacký University Olomouc
1516 - Real-World Outcomes of Idelalisib in Relapsed/Refractory CLL Including High-Risk Patients and Post-BTKi/BCL2 Therapy: A Single-Center Experience from 2016 to 2025
Renata Urbanová
Favorite
Urrutia, Jazmin

The Ohio State University
1801 - Targeting BTKi-Resistant CLL Using the Dual Irreversible/Reversible 4th Generation BTK Inhibitor Rocbrutinib
Jazmin Urrutia
Favorite